ATC Group: L01EB03 Afatinib

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01EB03 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01E Protein kinase inhibitors
4 L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
5 L01EB03 Afatinib

Active ingredients in L01EB03

Active Ingredient Description
Afatinib

Afatinib is a potent and selective, irreversible ErbB Family Blocker. Afatinib covalently binds to and irreversibly blocks signalling from all homo- and heterodimers formed by the ErbB family members EGFR (ErbB1), HER2 (ErbB2), ErbB3 and ErbB4.

Related product monographs

Title Information Source Document Type  
GIOTRIF Film-coated tablets European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

Australia (AU)

Austria (AT)

Brazil (BR)

Canada (CA)

Croatia (HR)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Japan (JP)

Lithuania (LT)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Romania (RO)

Singapore (SG)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.